Replication and secretion of hepatitis B virus variants

乙型肝炎病毒变异体的复制和分泌

基本信息

  • 批准号:
    6557207
  • 负责人:
  • 金额:
    $ 15.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-01 至 2005-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) infects 400 million people worldwide and causes hepatitis, cirrhosis, and liver cancer. HBV related liver diseases are the outcome of complex interplay between the virus and its host. Core promoter mutants are prevalent HBV variants with reduced HBeAg expression, which replace the wildtype strains in the late HBe and anti-HBe stages of infection. Such mutants have been implicated in fulminant hepatitis. The replication capacity of core promoter mutants remains controversial. The current approach introduces the most common core promoter mutations at 1762/1764 into wild-type HBV genome, and is thus flawed in omitting other core promoter mutations and co-evolved mutations elsewhere in the genome. The novelty of our approach is to test whether naturally occurring core promoter mutants replicate more efficiently than wild-type strains. We have identified two core promoter mutants (4B and 3.4) that replicated at 10 and 5 fold higher levels than wild-type isolates, respectively. Both harbored 1762/1764 and additional mutation(s). 4B secreted viral particles to culture supernatant at 4 times higher efficiency than 3.4. Moreover, 4B secreted both enveloped viral particles and naked core particles while 3.4 failed to secrete enveloped particles. The present study plans to further characterize the replication and secretion phenotypes of naturally occurring core promoter mutants. First, we will study the replication capacity of naturally occurring core promoter mutants. We plan to establish whether high replication capacity is a common feature of naturally occurring core promoter mutants. The sequence responsible for enhanced replication of 4B will be narrowed down by chimeric constructs with a low replicating clone. In a separate approach, the contribution of core promoter mutations to the high replication phenotype will be verified directly. Second, the mechanism for different secretion phenotypes of 3.4 versus 4B will be determined. The responsible sequence element will be mapped by mosaic constructs between 3.4 and 4B. Whether altered secretion is mediated by variant surface or core protein will be determined. The viral replication and secretion as studied here are basic features of the virus with profound effect on disease severity, response to therapy and recovery. Increase in replication and decrease in secretion may help induce severe liver diseases including fulminant hepatitis.
描述(由申请人提供):丙型肝炎病毒(HBV)感染了全球4亿人,并引起肝炎,肝硬化和肝癌。与HBV相关的肝病是病毒与其宿主之间复杂相互作用的结果。核心启动子突变体是普遍的HBV变体,其HBEAG表达降低,它取代了晚期HBE和抗HBE感染阶段的野生型菌株。这种突变体与暴发性肝炎有关。核心启动子突变体的复制能力仍然存在争议。当前的方法将1762/1764最常见的核心启动子突变引入了野生型HBV基因组中,因此在省略了其他基因组中其他地方的其他核心启动子突变和共同发展的突变方面存在缺陷。我们方法的新颖性是要测试自然发生的核心启动子突变体是否比野生型菌株更有效地复制。我们已经确定了两个核心启动子突变体(4b和3.4),它们分别比野生型分离株复制了10和5倍。均设有1762/1764和其他突变(S)。 4b分泌的病毒颗粒培养上清液的效率高于3.4的4倍。此外,4B分泌包裹的病毒颗粒和裸核颗粒,而3.4未能分泌包裹的颗粒。本研究计划进一步表征天然发生的核心启动子突变体的复制和分泌表型。首先,我们将研究自然存在的核心启动子突变体的复制能力。我们计划确定高复制能力是否是天然发生的核心启动子突变体的共同特征。负责增强4B复制的序列将通过具有低复制克隆的嵌合构建体来缩小。在另一种方法中,将直接验证核心启动子突变对高复制表型的贡献。其次,将确定3.4对4B的不同分泌表型的机制。负责的序列元件将由3.4和4b之间的镶嵌构建体映射。将确定分泌改变的分泌是否由变异表面或核心蛋白介导。此处研究的病毒复制和分泌是病毒的基本特征,对疾病严重程度,对治疗和康复的反应产生了深远的影响。复制的增加和分泌减少可能有助于诱导包括暴发性肝炎在内的严重肝病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHUPING TONG其他文献

SHUPING TONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHUPING TONG', 18)}}的其他基金

Explore furin as an antiviral target to block hepatitis B virus e antigen production
探索弗林蛋白酶作为抗病毒靶点来阻断乙型肝炎病毒 e 抗原的产生
  • 批准号:
    10352854
  • 财政年份:
    2021
  • 资助金额:
    $ 15.4万
  • 项目类别:
Explore furin as an antiviral target to block hepatitis B virus e antigen production
探索弗林蛋白酶作为抗病毒靶点来阻断乙型肝炎病毒 e 抗原的产生
  • 批准号:
    10495261
  • 财政年份:
    2021
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus transcriptional interference and liver cancer-related mutations
乙型肝炎病毒转录干扰与肝癌相关突变
  • 批准号:
    9089897
  • 财政年份:
    2015
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus transcriptional interference and liver cancer-related mutations
乙型肝炎病毒转录干扰与肝癌相关突变
  • 批准号:
    8969082
  • 财政年份:
    2015
  • 资助金额:
    $ 15.4万
  • 项目类别:
2013 International Meeting on the Molecular Biology of Hepatitis B Viruses
2013年乙型肝炎病毒分子生物学国际会议
  • 批准号:
    8526887
  • 财政年份:
    2013
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus genotypes B and C
乙型肝炎病毒基因型 B 和 C
  • 批准号:
    8428335
  • 财政年份:
    2013
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus genotypes B and C
乙型肝炎病毒基因型 B 和 C
  • 批准号:
    8605164
  • 财政年份:
    2013
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus immune escape mutants
乙型肝炎病毒免疫逃逸突变体
  • 批准号:
    7585771
  • 财政年份:
    2008
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus immune escape mutants
乙型肝炎病毒免疫逃逸突变体
  • 批准号:
    7470857
  • 财政年份:
    2008
  • 资助金额:
    $ 15.4万
  • 项目类别:
Hepatitis B virus e antigen expression
乙型肝炎病毒e抗原表达
  • 批准号:
    6722792
  • 财政年份:
    2003
  • 资助金额:
    $ 15.4万
  • 项目类别:

相似海外基金

Replication and secretion of hepatitis B virus variants
乙型肝炎病毒变异体的复制和分泌
  • 批准号:
    6768813
  • 财政年份:
    2003
  • 资助金额:
    $ 15.4万
  • 项目类别:
DISSECTING PRION DISEASE MECHANISMS WITH TRANSGENIC MICE
用转基因小鼠剖析朊病毒疾病机制
  • 批准号:
    2891477
  • 财政年份:
    1998
  • 资助金额:
    $ 15.4万
  • 项目类别:
DISSECTING PRION DISEASE MECHANISMS WITH TRANSGENIC MICE
用转基因小鼠剖析朊病毒疾病机制
  • 批准号:
    6187545
  • 财政年份:
    1998
  • 资助金额:
    $ 15.4万
  • 项目类别:
DISSECTING PRION DISEASE MECHANISMS WITH TRANSGENIC MICE
用转基因小鼠剖析朊病毒疾病机制
  • 批准号:
    2671148
  • 财政年份:
    1998
  • 资助金额:
    $ 15.4万
  • 项目类别:
FUNCTIONAL STUDIES WITH HIV-1 VPR
HIV-1 VPR 的功能研究
  • 批准号:
    2330352
  • 财政年份:
    1989
  • 资助金额:
    $ 15.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了